Antibody-drug conjugates (ADC), a fast-growing next-generation cancer treatment, have become an investment hotspot due to its potential to become mainstream globally, according to biopharmaceutical industry insiders.

📰

Continue Reading on South China Morning Post

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →